Biologics Manufacturing Companies to Remain the Most Sought-After Targets for Acquisitions
There has been a significant rise in the number of mergers & acquisition activities in the contract manufacturing industry in recent years, with assets of drug manufacturing capabilities being the prime focus. Greater tendency of big pharma companies to build in-house production facilities apropos of biologics has resulted in outsourcing of packaging stages and secondary manufacturing activities. Recognizing the upward trend of drug formulation outsourcing and growth prospective of secondary manufacturing space, contract manufacturing organizations (CMOs) are enhancing their capacities...
View full press release